Analysts Set Tenax Therapeutics, Inc. (NASDAQ:TENX) Target Price at $16.00

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have earned a consensus rating of “Buy” from the five brokerages that are presently covering the company, MarketBeat reports. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $16.00.

Several equities analysts recently issued reports on the stock. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They set a “sell” rating on the stock. Leerink Partners assumed coverage on shares of Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 price objective on the stock. Guggenheim assumed coverage on shares of Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. Finally, William Blair assumed coverage on shares of Tenax Therapeutics in a research note on Monday, September 30th. They set an “outperform” rating on the stock.

Hedge Funds Weigh In On Tenax Therapeutics

Large investors have recently bought and sold shares of the stock. Vestal Point Capital LP acquired a new stake in shares of Tenax Therapeutics in the third quarter worth $288,000. Stonepine Capital Management LLC acquired a new stake in shares of Tenax Therapeutics in the third quarter worth $173,000. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Tenax Therapeutics in the third quarter worth $101,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Price Performance

Shares of TENX opened at $6.24 on Wednesday. The company’s 50 day simple moving average is $5.53 and its 200 day simple moving average is $4.31. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $21.46.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.